Serum CEA and CYFRA Levels in ALK-rearranged NSCLC Patients: Correlation With Distant Metastasis

Abstract

Aim: To clarify the correlation between serum levels of carcinoembryonic antigen (CEA) and cytokeratin 19 fragment (CYFRA) and metastasis and survival in anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) patients. Patients and Methods: CEA and CYFRA levels in 131 ALK-rearranged NSCLC patients were determined using fluorescence in situ hybridization (FISH), real time-reverse transcription polymerase chain reaction, and immunohistochemistry, using biopsy specimens, cytology specimens, and plasma specimens. Cutoff value of each marker was determined as 10 ng/ml. Results: In logistic regression analysis, higher levels of both markers had a positive relationship with bone metastases, and higher levels of CYFRA was relevant to liver metastases, and multiple-organ metastases. However, these markers were not proven to be poor prognostic factors in Cox's proportional model analysis. Conclusion: Elevated serum CEA and CYFRA levels seem to provide useful clinical information about presence of bone and liver metastasis and multiple-organ metastases, although they were not a powerful indicator of prognosis. These two markers may suggest the extension of metastasis and would be helpful in considering treatment options. Carcinoembryonic antigen (CEA) has been widely used in clinical practice as a serum tumor marker for non-small cell lung cancer (NSCLC) patients (1). Cytokeratin 19 fragment (CYFRA) is also one of the representative serum tumor markers used for detection of NSCLC patients in clinical practice (1). CEA is a glycoprotein and CYFRA is a soluble 2095 This article is freely accessible online.

Predictive and Prognostic Biomarkers for Lung Cancer Bone Metastasis and Their Therapeutic Value

“…CEA is also widely used in clinical practice as a serum marker for NSCLC. Recently, Numata et al concluded that elevated serum CEA and CYFRA levels were associated with the presence of bone and liver metastasis and also multiple-organ metastases; however, these high levels were not a powerful indicator of prognosis (38). Furthermore, serum CEA and CYFRA had predictive value with regard to response to therapy in NSCLC, and decreased levels of CYFRA are indicative of objective response (182).…”

“…Kong et al. ( 37 ) compared the clinical effect of serum β-type collagen carboxy-terminal peptide and I-CTP in 126 patients, demonstrating that the latter has higher sensitivity and accuracy with a similiar receiver operating characteristic curve [area under the curve ( 38 )] value. Tang et al.…”

Carcinoembryonic antigen in the diagnosis, treatment, and follow-up of focal liver lesions

“…In 30% of Stage 1 NSCLC cases, lymph node metastasis is present at the time of diagnosis. Elevated levels of CEA and cytokeratin 19 fragment combination in NSCLC cases may serve as an indicator of liver metastasis and distant organ metastases[ 10 , 50 , 51 ]. In cases where radiological imaging is insufficient and CEA levels are elevated, additional imaging modalities (PET/CT, bronchoscopic ultrasound, and thoracoscopic examinations) may assist in the diagnosis.…”

Multiparameter prediction model of immune checkpoint inhibitors combined with chemotherapy for non-small cell lung cancer based on support vector machine learning

“…Therefore, high level of hemoglobin, might indicating an oxygen-enriched environment which is characterized by having higher nutrient availability and by being rather immunostimulatory, was associated with a more efficient treatment response. (4) CFYRA21-1: serum level of CFYRA21-1 is related to the tumor size, lymph node status, distant Metastasis and the stage of disease 29 , 30 which could assist in predicting immunotherapy efficacy 31 and baseline level was positively correlated with the patient’s risk score before immunotherapy 32 .…”